0HA3 Stock Overview
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Adverum Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.31 |
| 52 Week High | US$29.50 |
| 52 Week Low | US$7.40 |
| Beta | 0.79 |
| 1 Month Change | -29.57% |
| 3 Month Change | 33.83% |
| 1 Year Change | 25.37% |
| 3 Year Change | -87.57% |
| 5 Year Change | -79.44% |
| Change since IPO | -83.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HA3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -1.8% | -1.9% | -0.9% |
| 1Y | 25.4% | -30.5% | -1.8% |
Return vs Industry: 0HA3 exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0HA3 exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0HA3 volatility | |
|---|---|
| 0HA3 Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HA3's share price has been volatile over the past 3 months.
Volatility Over Time: 0HA3's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 121 | Laurent Fischer | adverum.com |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. Fundamentals Summary
| 0HA3 fundamental statistics | |
|---|---|
| Market cap | US$235.36m |
| Earnings (TTM) | -US$117.16m |
| Revenue (TTM) | US$3.60m |
65.4x
P/S Ratio-2.0x
P/E RatioIs 0HA3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HA3 income statement (TTM) | |
|---|---|
| Revenue | US$3.60m |
| Cost of Revenue | US$77.68m |
| Gross Profit | -US$74.08m |
| Other Expenses | US$43.09m |
| Earnings | -US$117.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.65 |
| Gross Margin | -2,057.67% |
| Net Profit Margin | -3,254.58% |
| Debt/Equity Ratio | 0% |
How did 0HA3 perform over the long term?
See historical performance and comparison